Alnylam Pharmaceuticals | ALNY - Pre Tax Profit

Stock Price
328.16
Daily Change
-3.08 -0.93%
Monthly
-22.33%
Yearly
18.82%
Q1 Forecast
327.65

Alnylam Pharmaceuticals reported $238.97M in Pre-Tax Profit for its fiscal quarter ending in September of 2025.





Pre Tax Profit Change Date
Acadia Pharmaceuticals USD 44.6M 4.38M Sep/2025
Agios Pharmaceuticals USD -103.43M 8.59M Sep/2025
Alnylam Pharmaceuticals USD 238.97M 274.33M Sep/2025
Amgen USD 3.92B 2.35B Sep/2025
Arrowhead Research USD 28.27M 7.85M Dec/2025
BioMarin Pharmaceutical USD -26.32M 324.19M Sep/2025
Incyte USD 482.31M 75.7M Sep/2025
Ionis Pharmaceuticals USD -129M 253M Sep/2025
Moderna USD -187M 631M Sep/2025
Neurocrine Biosciences USD 291.8M 132.3M Sep/2025
Novartis USD 5.17B 637M Sep/2025
PTC Therapeutics USD -23.07M 47.98M Sep/2025
Regeneron Pharmaceuticals USD 1.76B 244.6M Sep/2025
Sanofi EUR -1.16B 6.23B Dec/2025
Sarepta Therapeutics USD -194.05M 347.69M Sep/2025
Takeda JPY 133.86B 105.69B Dec/2025
Tectonic Therapeutic USD -19.04M 25K Sep/2025
Ultragenyx Pharmaceutical USD -179.54M 65.54M Sep/2025
Vertex Pharmaceuticals USD 1.3B 15.8M Sep/2025
Xencor USD -6.03M 25.05M Sep/2025